The closing price of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) was $4.93 for the day, down -1.20% from the previous closing price of $4.99. In other words, the price has decreased by -$0.0600 from its previous closing price. On the day, 947893 shares were traded. AUPH stock price reached its highest trading level at $5.0600 during the session, while it also had its lowest trading level at $4.9300.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our analysis of AUPH’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.99 and its Current Ratio is at 5.50. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.22.
Oppenheimer Upgraded its Perform to Outperform on December 10, 2021, whereas the target price for the stock was revised from $33 to $31.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 06 ’24 when Greenleaf Peter sold 126,981 shares for $5.60 per share. The transaction valued at 711,094 led to the insider holds 1,522,114 shares of the business.
Robertson Stephen P. sold 57,745 shares of AUPH for $323,372 on Mar 06 ’24. The EVP, General Counsel now owns 443,824 shares after completing the transaction at $5.60 per share. On Mar 06 ’24, another insider, Donley Matthew Maxwell, who serves as the EVP, Ops & Strategy of the company, sold 40,665 shares for $5.51 each. As a result, the insider received 224,064 and left with 584,072 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUPH now has a Market Capitalization of 712.97M and an Enterprise Value of 460.08M. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.06 while its Price-to-Book (P/B) ratio in mrq is 1.88. Its current Enterprise Value per Revenue stands at 2.62 whereas that against EBITDA is -7.30.
Stock Price History:
The Beta on a monthly basis for AUPH is 1.37, which has changed by -56.26% over the last 52 weeks, in comparison to a change of 29.19% over the same period for the S&P500. Over the past 52 weeks, AUPH has reached a high of $12.43, while it has fallen to a 52-week low of $4.94. The 50-Day Moving Average of the stock is 6.5504, while the 200-Day Moving Average is calculated to be 8.4111.
Shares Statistics:
AUPH traded an average of 2.41M shares per day over the past three months and 1.54M shares per day over the past ten days. A total of 143.83M shares are outstanding, with a floating share count of 127.86M. Insiders hold about 11.59% of the company’s shares, while institutions hold 36.53% stake in the company. Shares short for AUPH as of Feb 29, 2024 were 12.1M with a Short Ratio of 5.02, compared to 18.53M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 8.37% and a Short% of Float of 8.40%.
Earnings Estimates
The firm’s stock currently is rated by 6 analysts. On average, analysts expect EPS of -$0.14 for the current quarter, with a high estimate of $0.01 and a low estimate of -$0.2, while EPS last year was -$0.18. The consensus estimate for the next quarter is -$0.02, with high estimates of $0.04 and low estimates of -$0.06.
Analysts are recommending an EPS of between $0.15 and -$0.34 for the fiscal current year, implying an average EPS of -$0.05. EPS for the following year is $0.39, with 6 analysts recommending between $0.83 and -$0.14.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $51.82M to a low estimate of $46M. As of the current estimate, Aurinia Pharmaceuticals Inc’s year-ago sales were $34.41M, an estimated increase of 37.90% from the year-ago figure.
A total of 6 analysts have provided revenue estimates for AUPH’s current fiscal year. The highest revenue estimate was $232.83M, while the lowest revenue estimate was $207M, resulting in an average revenue estimate of $224.25M. In the same quarter a year ago, actual revenue was $175.51M, up 27.80% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $288.87M in the next fiscal year. The high estimate is $339.89M and the low estimate is $250M. The average revenue growth estimate for next year is up 28.80% from the average revenue estimate for this year.
